---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-069625"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:30:14.796484+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CARA shareholders approve doubling authorized shares and authorize reverse stock split

## Summary
- Authorized common stock increased from 100M to 200M shares; 76.5% of votes in favor.
- Board authorized to implement reverse stock split at ratio 1:4 to 1:12, with proportionate reduction in authorized shares.
- Directors Susan Shiff and Helen Boudreau elected; advisory say-on-pay passed with 16.3M for vs 10.7M against.
- Ernst & Young ratified as independent auditor for FY2024.

## SEC filing metadata
- accession: 0001104659-24-069625
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465924069625/0001104659-24-069625-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465924069625/tm2416682d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-069625
- JSON: https://secwatch.observer/filing/0001104659-24-069625.json
- Plain text: https://secwatch.observer/filing/0001104659-24-069625.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.